ImmunoPrecise Antibodies, founded in 1983, is a biotech and biotherapeutic research company headquartered in Austin, Texas. The organization has established a reputation for novel pharmaceutical solutions based on the fusion of industry-leading antibody discovery services and advanced artificial intelligence systems. ImmunoPrecise Antibodies also actively pursues opportunities with disruptive technologies and biotherapeutic drug discovery platforms.
ImmunoPrecise Antibodies (IPA) has received the highest possible rating for the company’s antibody service portfolio from the pharmaceutical industry’s most reputable independent market research sources. They have garnered many additional honors and accolades for individual products and programs; the company’s subsidiary, BioStrand, won the 2024 InterSystems Impact Award in recognition of the LENSai platform, which beat out more than 1,000 biotherapeutic research projects from around the world.
In addition to its dedication to defeating deadly and debilitating diseases, IPA has contributed to the greater field by making donations to groups such as the Damon Runyon Cancer Research Foundation. IPA also gives back by participating in educational collaborations with companies like AMD and Vultr.